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ABSTRACT
Rapamycin prevention of murine graft-versus-host disease (GVHD) is associated with a shift toward Th2- and
Tc2-type cytokines. Recently, we found that use of rapamycin during ex vivo donor Th2 cell generation
enhances the ability of adoptively transferred Th2 cells to prevent murine GVHD. In this study, using a
method, without antigen-presenting cells, of T-cell expansion based on CD3,CD28 costimulation, we evalu-
ated whether (1) rapamycin preferentially promotes the generation of Th2/Tc2 cells relative to Th1/Tc1 cells,
(2) rapamycin-generated T-cell subsets induce cytokine skewing after allogeneic bone marrow transplantation
(BMT), and (3) such in vivo cytokine skewing is sensitive to post-BMT rapamycin therapy. Contrary to our
hypothesis, rapamycin did not preferentially promote Th2/Tc2 cell polarity, because rapamycin-generated
Th1/Tc1 cells secreted type I cytokines (interleukin [IL]-2 and interferon-) did not secrete type II cytokines
(IL-4, IL-5, IL-10, or IL-13) and mediated fasL-based cytolysis. Rapamycin influenced T-cell differentiation,
because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the
central-memory T-cell marker, L-selectin (CD62L). Rapamycin-generated Th1/Tc1 and Th2/Tc2 cells were
not anergic but instead had increased expansion after costimulation in vitro, increased expansion in vivo after
BMT, and maintained full capacity to skew toward type I or II cytokines after BMT, respectively; further,
rapamycin-generated Th1/Tc1 cells mediated increased lethal GVHD relative to control Th1/Tc1 cells.
Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1
cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin
therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells
in vivo and did not abrogate post-BMT type II cytokine skewing. In conclusion, ex vivo and in vivo usage of
rapamycin may be used to modulate the post-BMT balance of Th1/Tc1 and Th2/Tc2 cell subsets.
© 2006 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Rapamycin (sirolimus) has been shown to reduce
urine graft-versus-host disease (GVHD) [1] and has
ecently demonstrated activity for the prevention [2,3]
r therapy [4-6] of human GVHD. The molecular
echanism of rapamycin action involves drug binding
o the immunophilin FKBP-12 [7] and subsequent
nhibition of the mammalian target of rapamycin [8]. sowever, the cellular mechanisms of rapamycin ac-
ion, particularly as they relate to allogeneic transplan-
ation, are less well deﬁned and appear to include
odulation of antigen-presenting cells (APCs) for im-
une suppression by non–T-cell–mediated “indirect”
ffects [9], induction of regulatory cells that mediate
mmunosuppressive effects within GVHD target tis-
ue [10], promotion of donor T-cell tolerance to host
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U. Jung et al.906lloantigen during CD28 costimulation [11], and po-
arization after transplantation of T-cell subsets to-
ard CD4Th2 and CD8Tc2 phenotypes [12,13].
Given this association of rapamycin therapy with
ype II cytokine polarization, we recently evaluated
hether rapamycin might be used in vitro during
onor CD4Th2 cell generation to enhance Th2 cell-
ased GVHD prevention strategies [14]. In these ex-
eriments, we found that: (1) when using CD3, CD28
ostimulation and interleukin (IL)-4–based culture
onditions, Th2 cell differentiation proceeded in the
resence of high-dose rapamycin (10 M); (2) relative
o control Th2 cells, rapamycin-generated Th2 cells
Th2.rapa cells) more effectively upregulated type II cy-
okines, downregulated type I cytokines, and inhibited
llospeciﬁc T-cell responses after bone marrow trans-
lantation (BMT); and (3) Th2.rapa cells potently abro-
ated GVHD and graft-versus-tumor (GVT) effects
hrough a mechanism dependent in part on Th2 cell
L-4 secretion. These ﬁndings indicate that rapamycin
an be used exclusively in vitro to enhance Th2 cell
herapy, thereby permitting an anti-GVHD effect of
his drug to be used without potential for in vivo drug
oxicity.
In the present project, we further characterized the
nﬂuence of rapamycin on T-cell subset generation in
itro and evaluated the effect of in vivo post-BMT rapa-
ycin therapy on the post-BMT balance of rapamycin-
enerated, polarized, effector T cells. First, by using our
stablished methods of T-cell polarization after APC-
ree costimulation, we tested whether the capacity to
enerate cytokine-polarized effector T cells in high-
ose rapamycin could be generalized from our prior
bservations relating to CD4Th2 cells to the
D4Th1, CD8Tc1, and CD8Tc2 subsets. Sec-
nd, we evaluated whether rapamycin might inﬂuence
olarized effector T-cell differentiation status into T
central memory” (TCM) cells that express the lymph
ode homing molecule L-selectin (CD62L) or T
effector memory” (TEM) cells that have reduced
D62L expression. Emerging data indicate that
CM status associates with enhanced in vivo effects
fter adoptive T-cell therapy, because unmanipulated
D62L-expressing allogeneic T cells mediate in-
reased GVHD [15,16], CD62L-expressing alloge-
eic T regulatory cells have an increased capacity to
revent GVHD [17,18], and antigen-speciﬁc CD62L-
xpressing syngeneic T cells mediate increased anti-
umor effects [19]. Third, we evaluated whether cyto-
ine-polarized effector T cells generated in the
resence of high-dose rapamycin maintain resistance
o rapamycin in vivo after BMT. We reasoned that
-cell rapamycin resistance, which has been described
n human CD8 T cells [20], might allow further
kewing in the post-BMT balance of Th1/Tc1 and
h2/Tc2 populations during rapamycin therapy. tETHODS
nimals
C57BL/6 BALB/c F1 (CB6F1, H-2K
b/d), BALB/c
H-2Kd), C57BL/6 (B6, H-2Kb; Ly5.2), and Ly5.1 con-
enic (H-2Kb) mice were obtained from Frederick
ancer Research Facility (Frederick, Md). Thy1.1
ongenic (H-2Kb) mice were obtained from Jackson
aboratory (Bar Harbor, Me). Mice were maintained
n a speciﬁc pathogen-free facility at the National
nstitutes of Health and treated according to an ap-
roved animal protocol.
eneration of Th1/Tc1 and Th2/Tc2 Subsets
sing CD3 and CD28 Costimulation
Spleens were harvested and ACK lysed (Quality
iological, Inc, Gaithersburg, Md). B cells were de-
leted using goat anti-mouse immunoglobulin G bio-
articles (Polysciences Inc, Warrington, Pa). Result-
nt splenic T cells were used for generation of Th1/
c1 or Th2/Tc2 cells. To generate antibody-coated
eads, M450 Dynabeads (Dynal, Oslo, Norway) were
ncubated with anti-murine CD3 and CD28 mono-
lonal antibodies (mAbs; BD PharMingen, San Diego,
alif) in 0.1 M borate solution at 37°C overnight, as
escribed previously [21,22]. CD3, CD28 mAb-coated
eads were washed with phosphate buffered saline con-
aining 3% fetal bovine serum (Gemini Bio-Products,
oodland, Calif), 5 mM ethylenediaminetetraacetic
cid (Quality Biological, Inc), and 0.1% sodium azide
Sigma, St Louis, Mo) and resuspended at a bead con-
entration of 40  106 beads/mL. Costimulation was
erformed at a bead-to–T-cell ratio of 3:1.
Complete media for T-cell culture contained RPMI
640 (Mediatech, Herndon, Va), 10% fetal bovine se-
um (Gemini Bio-Products), penicillin-streptomycin-
lutamine (Life Technologies; Rockville, Md), nones-
ential amino acids (Life Technologies), and
-mercaptoethanol (Sigma). Rapamycin (sirolimus)
as purchased from LC Labs (Woburn, Mass). Media
sed to generate Th1/Tc1 cells consisted of recombi-
ant human (rh) IL-2 (20 IU/mL; National Cancer
nstitute Repository, Rockville, Md), rhIL-7 (20 ng/
L; Peprotech, Rocky Hill, NJ), recombinant mu-
ine (rm) IL-12 (10 ng/mL; Peprotech), anti-murine
L-4 mAb (clone 11B.11; 10 g/mL; National Can-
er Institute Repository), and 3.3 mM N-acetyl-
ysteine (Bristol-Myers Squibb, Princeton, NJ).
edium used to generate Th2/Tc2 cells was sup-
lemented with rhIL-2 (1000 IU/mL), rhIL-7 (20
g/mL), rmIL-4 (1000 IU/mL; Peprotech), and N-
cetyl-cysteine (3.3 mM). Cytokine-containing
omplete medium was added to cultures daily from
ays 2 to 6 to maintain cell concentration of 0.2-1.0
106 cells/mL; however, rmIL-12 was added only on
ay 0 of culture. Costimulated T cells were pheno-
yped by enzyme-linked immunosorbent assay
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Rapamycin-Generated Murine Th1/Tc1 and Th2/Tc2 Cells 907ELISA), cytotoxic T lymphocyte (CTL) assay, and
uorescence-activated cell sorting on day 6 of culture.
ytokine Secretion Profile by ELISA
Costimulated T cells were harvested, washed, and
esuspended at 0.5 106 cells/mL with no stimulation
r repeat costimulation. Supernatants were collected
fter 24 hours and cytokine content was evaluated by
-site ELISA (IL-2 and IL-5: R&D Systems, Minne-
poli, Minn; IL-4, IL-10, IL-13, and interferon-
IFN-]: BioSource; Camarillo, Calif).
TL Assays
Costimulated T cells were evaluated for cytolytic
apacity by standard 51Cr-release assays. Target cell lines
sed for CTL assays were provided by Dr P. Henkart
National Institutes of Health, Bethesda, Md); targets
ere labeled with 51Cr (Amersham; Buckinghamshire,
ngland). For assays measuring granule-based killing,
arget cells were P815 cells coated with anti-murine
D3 mAb (clone 2C11; BD PharMingen); effector
cells were used without secondary stimulation. For
as-based killing, target cells were L1210-fas–trans-
ected and nontransfected L1210 cells; effector T cells
ere stimulated with phorbol ester (PMA, 5 ng/mL;
igma) and calcium ionophore (CI, 375 ng/mL;
igma) for 24 hours before CTL assay. To inhibit
xocytosis-based killing [23], fas-based CTL assays were
erformed in calcium-neutralized conditions (5mM eth-
lene glycol bis (2-aminoethyl ether)-N,N,N=N=-tet-
aacetic acid (EGTA), 0.5 mMgCl2; Sigma). Super-
atants were collected 8 hours after effector and target
ell coincubation, transferred to LumaPlates (Packard,
eriden, Conn), and read (Microplate Scintillation
nd Luminescence Counter, Packard). Percent spe-
iﬁc lysis was then calculated.
urface Phenotype of Th1/Tc1 and Th2/Tc2 Cells
y Flow Cytometry
On days 0 and 6 of culture, T cells were harvested
nd brought to a ﬁnal concentration of 0.5  106
ells/mL; T cells received no further stimulation or
ere stimulated for 24 hours with PMA/CI. Antibod-
es used included anti-murine CD4, CD8, CD62L,
nd CD44 conjugated to ﬂuorescein isothiocyanate,
hycoerythrin, or allophycocyanin (APC) (BD
harMingen). Three-color ﬂuorescence-activated cell
orting was performed with FACSCalibur (BD Bio-
ciences, San Jose, Calif) and CellQuest software (BD
iosciences). To determine CD62L expression on
h2 cells or rapamycin-generated Th2 cells at cell
ivisions 0 through 4, cultures were initiated with
D4 T cells labeled with 1 M 5(6)-carboxyﬂuores-
ein diacetate succinimidyl ester (CFSE; Molecular
robes, Eugene, Ore); cell division number was cal-
ulated by successive 50% dilution in CFSE intensi- uies on gated CD4 T cells. Five to ten thousand live
vents were acquired for analysis, with propidium io-
ide exclusion of dead cells.
numeration of T1 and T2 Cells In Vivo after
llogeneic BMT
To facilitate T-cell tracking after BMT, parental
6 T1 and T2 cells were generated from Thy1.1 and
y5.1 donors, respectively, with or without rapamycin
dded to culture. In some experiments, to determine
-cell proliferation in vivo, polarized T cells were la-
eled with CFSE. CB6F1 hosts were lethally irradiated
1100 cGy; 137Cs gamma-radiation source; Gamma Cell
0, Atomic Energy of Canada, Ottawa, Canada) and
econstituted intravenously with parental B6 bone mar-
ow cells (Ly5.2). To maintain consistency with our
rior model [22], host mice also received breast cancer
ells (intravenously; TS/A cells [24]; H-2d; 0.1  106
ells); however, determination of the potential inﬂu-
nce of T1 versus T2 cells on an allogeneic GVT
ffect was not possible, because tumor cells were not
onsistently detected in vivo at day 5 after BMT. Bone
arrow transplant was supplemented with a 1:1 ratio
f Th1/Tc1 and Th2/Tc2 cells through separate in-
ravenous injections (5  106 of each population);
ther control groups received 1  107 T cells of only
h1/Tc1 or Th2/Tc2 phenotype. Rapamycin therapy
as administered (intraperitoneally) at a previously de-
cribed dose of 1.5 mg · kg1 · d1 [13]; control mice
eceived intraperitoneal injection of the drug vehicle,
arboxy-methyl-cellulose (CMC; Sigma). On day 5
fter BMT, spleen cell number was determined, and
D4Th1, CD8Tc1, CD4Th2, and CD8Tc2
opulations were identiﬁed by ﬂow cytometry using
nti-CD4, anti-CD8, anti-CD45.1, and anti-CD90.1
BD PharMingen).
To analyze the effect of ex vivo or in vivo rapa-
ycin on lethal GVHD, B6-into-BALB/c BMT was
erformed using 850 cGy of host irradiation followed
y marrow infusion (1  107 cells/recipient) and sepa-
ate infusion of ex vivo-generated control or rapamycin-
xposed Th1/Tc1 cells (1  107 Th1/Tc1 cells/recipi-
nt). Mice that underwent transplantation received in
ivo rapamycin (1.5 mg · kg1 · d1  5 days) or con-
rol CMC drug vehicle and were then evaluated daily
or survival; premorbid transplant recipients were eu-
hanized.
etermination of Post-transplant
ytokine Polarization
Splenic single-cell suspensions were obtained on
ay 5 after BMT. After determination of total spleen
ell number, cells were adjusted to 0.5  106 cells/mL
ith no further stimulation or stimulation with anti-
D3, anti-CD28 coated beads. After 24 hours, super-
atants were collected and cytokine content was eval-
ated using 2-site ELISA.
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Group comparisons were by paired Student t test;
 .05 was considered statistically signiﬁcant. For
urvival analysis, Wilcoxon nonparametric rank-sum
nalysis was used.
ESULTS
apamycin Limits But Does Not Abrogate
h1/Tc1 and Th2/Tc2 Cell Expansion
T cells expanded approximately 100-fold over 6
ays in culture after costimulation in Th1/Tc1 (T1)
r Th2/Tc2 (T2) polarizing conditions in the ab-
ence of rapamycin (Figure 1A,B). Rapamycin in-
ibited T-cell expansion by approximately 1 log in
1 and T2 conditions at the lowest concentration
ested (0.0008 M); higher concentrations of rapa-
ycin (up to 10 M) resulted in further incremental
eductions in T-cell yield. CD4Th2 cells had reduced
ensitivity to rapamycin inhibition, as evidenced by the
igure 1. Effect of rapamycin (Rapa) on T-cell expansion under type I
nti-CD28–coated beads in the presence of IL-12 and anti–IL-4 (typ
ncreases in T-cell number are shown for T1 (A) and T2 (B) cultur
.004 M (), 0.02 M (), 0.1 M (), and 10 M (Œ). Results show
rom separate donors and run in parallel; each T1 and T2 culture in rapa
n day 7, cultures were tested by ﬂow cytometry to determine the effe
esults shown are mean  SEM of 5 replicates for each culture condincreased the CD4:CD8 ratio compared with control cultures not receiving rancreased CD4:CD8 ratio in the T2 culture condition
Figure 1D).
h1/Tc1 and Th2/Tc2 Polarization Proceeds in
he Presence of Rapamycin
Using this APC-free culture system, we next eval-
ated whether rapamycin inhibited Th1/Tc1 or Th2/
c2 cell polarization. T cells costimulated under type
polarizing conditions secreted the type I cytokines
L-2 and IFN- concomitant with nominal or unde-
ectable secretion of the type II cytokines IL-4, IL-5,
L-10, and IL-13 (Figure 2A); rapamycin, even at the
ighest dose tested (10 M), reduced type I cytokine
ecretion but did not induce type II cytokine secretion.
y comparison, T cells costimulated under type II po-
arizing conditions secreted high levels of type II cyto-
ines but also secreted type I cytokines (Figure 2B);
lthough rapamycin reduced the magnitude of type II
ytokine secretion, IL-4 secretion was relatively
pared, and type I cytokines were dramatically reduced.
olarizing conditions. Splenic T cells were costimulated with anti-CD3,
dition, T1) or in the presence of IL-4 (type II condition, T2). Fold
out rapamycin () or with rapamycin at doses of 0.0008 M (□),
ean values of 5 replicates for each culture condition that were generated
ad reduced expansion relative to culture without rapamycin (*P  .05).
pamycin on the CD4:CD8 ratio under T1 (C) and T2 (D) conditions.
t were generated from separate donors and run in parallel; rapamycinand II p
e I con
es with
n are m
mycin h
ct of ra
tion thapamycin (*P  .05).
I
T
c
i
C
T
o
p
l
s
r
u
2
t
e
i
i
i
R
C
s
p
(
ﬁ
s
B
t
A
C
T
t
F
(
(
w
o
h
w
a erated
Rapamycin-Generated Murine Th1/Tc1 and Th2/Tc2 Cells 909n sum, these data indicate that rapamycin modulated
-cell effector function by reducing the magnitude of
ytokine secretion, but did not directly impair the capac-
ty for T-cell polarization toward type I or II phenotypes.
ytolytic Function of Rapamycin-Generated
h1/Tc1 and Th2/Tc2 Cells
Similar to results that we and others previously
btained [22,25], the Th1/Tc1 population mediated
otent fas-based cytolysis (Figure 2C, left panel) and
imited killing by granule-mediated cytolysis (20%
peciﬁc lysis of P815 targets at a 30:1 effector:target
atio; data not shown). In contrast, the Th2/Tc2 pop-
lation mediated potent granule-based killing (Figure
C, right panel) and limited killing by fas-based cy-
olysis (20% lysis of L1210-fas targets at a 30:1
ffector:target ratio; data not shown). As Figure 2C
igure 2. Cytokine secretion proﬁle and cytolytic function of T1 and
B) cultures were harvested, washed, and resuspended at 0.5  106 ce
results shown). The 24-hour supernatants were evaluated by ELISA
ithout rapamycin, *P  .05). Rapamycin dose level “0” refers to no rap
f 0.0008, 0.004, 0.02, 0.1, and 10 M, respectively. C. To evaluate fas-ba
ours and coincubated with 51Cr-labeled L1210-fas targets in calcium-ne
ere coincubated in a heteroconjugate assay with 51Cr-labeled P815 target
re mean  SEM of 5 replicates for each culture condition that were genllustrates, generation of Th1/Tc1 and Th2/Tc2 cells sn rapamycin partly reduced T-cell cytolytic capacity
n a dose-dependent manner.
apamycin Increases Th1, Th2, Tc1, and Tc2
ell Expression of CD62L
As discussed in the Introduction, one goal of our
tudies was to characterize the effect of rapamycin on
olarized T-cell differentiation into central memory
TCM) versus effector memory (TEM) subsets as de-
ned by the presence or absence of CD62L expres-
ion, respectively. Of note, in previous experiments by
lazar et al [13], in vivo rapamycin therapy was shown
o increase post-BMT T-cell expression of CD62L.
fter costimulated T-cell expansion, all CD4 and
D8T cells propagated with or without rapamycin in
h1/Tc1 and Th2/Tc2 conditions attained memory sta-
us, as deﬁned by uniform expression of CD44 (data not
ctors generated with or without rapamycin. On day 6, T1 (A) and T2
with no stimulation (results not shown) or with repeat costimulation
okine content (reduced cytokine level compared with control culture
added, and dose levels 1, 2, 3, 4, and 5 reﬂect rapamycin concentrations
lytic function (left panel), T1 cells were stimulated with PMA/CI for 24
d conditions; to evaluate granule-dependent killing (right panel) T2 cells
ium-replete conditions. All values shown for cytokine and cytolytic assays
from separate donors and run in parallel. E:T  effector:target.T2 effe
lls/mL
for cyt
amycin
sed cyto
utralize
s in calchown). In the absence of rapamycin, CD62L was pref-
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U. Jung et al.910rentially expressed on expanded CD4 T cells relative
o CD8 T cells and preferentially expressed on Th1-
ype cells relative to Th2-type cells (Figure 3). In the
resence of rapamycin, even at a relatively low concen-
ration of 0.0008 M, costimulated Th1, Th2, Tc1,
nd Tc2 cells each expressed greatly increased
D62L. This effect was particularly dramatic for Th2
nd Tc2 cells, because these populations expressed
nly nominal CD62L in the absence of rapamycin.
urther, rapamycin-generated T-cell subsets main-
ained signiﬁcant expression of CD62L expression af-
er further T-cell activation; in marked contrast, Th1,
c1, Th2, and Tc2 cells generated without rapamycin
ere devoid of CD62L expression after restimulation.
apamycin upregulation of CD62L was observed if
ata were expressed in terms of mean ﬂuorescence
ntensity (MFI; Figure 3) or in terms of percentage of
ells positive; relative to the control cultures gen-
rated without rapamycin, the addition of low-dose
apamycin (0.0008 M) increased the percentage of
ells expressing CD62L for the Th1 subset (from 79.4
igure 3. Rapamycin augments Th1, Th2, Tc1, and Tc2 cell expre
ith rapamycin (at the concentrations shown) under T1 or T2 po
urther stimulation or with PMA/CI stimulation. On day 7, T ce
xpression; results for T cells not restimulated are shown as open b
xpressed as change in CD4 or CD8 cell expression of CD62L re
D4 and CD8 cells expanded in the T1 condition are shown in
ells expanded in the T2 condition are shown in the lower left and r
ells generated without rapamycin (*P  .05); values are mean  S
eparate donors and run in parallel..3% to 93.1  2.3%, P  .05), the Tc1 subset (from
8.9  1.3% to 96.6  0.3%, P  .05), the Th2 subset
from 34.0  1.1% to 95.8  1.0%, P  .05), and the
c2 subset (from 10.8 0.5% to 85.8 1.1%, P .05).
imilar increases in percentage of cells expressing
D62L were observed in the higher-dose rapamycin
onditions (data not shown).
Additional experiments using puriﬁed CD4 Th2
ell cultures were performed to further characterize
he effect of rapamycin on CD62L expression. CD4
ell expansion under control Th2 conditions resulted
n a rapid downregulation of CD62L expression (Fig-
re 4A; reduction from 52.2% CD4CD62L cells
n day 0 to 27.8  1.0% CD4CD62L cells on day
of culture); in marked contrast, in the rapamycin-
enerated Th2 cell culture, 71.1  1.0% of cells were
D4CD62L on day 2 of culture (increased relative
o control Th2 culture, P .0004). The percentage of
h2.rapa cells that expressed CD62L remained ele-
ated relative to input CD4 cells and to control Th2
ells at days 4, 5, and 6 of culture. We reasoned that
f CD62L. CD4 and CD8 T cells were costimulated without or
conditions. On day 6, T cells were incubated overnight without
e then evaluated by ﬂow cytometry for CD4, CD8, and CD62L
those for restimulated T cells are shown as solid bars. Results are
o isotype controls (mean ﬂuorescence intensity, MFI). Results for
er left and right panels, respectively; results for CD4 and CD8
els, respectively. CD62L expression is increased relative to control
f 5 replicates for each culture condition that were generated fromssions o
larizing
lls wer
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lative t
the upp
ight pan
EM o
t
q
c
i
M
d
a
r
t
v
t
c
i
f
c
T
d
v
d
v
t
o
o
R
E
m
T
i
C
c
i
s
w
p
o
w
c
i
t
h
s
R
E
e
T
d
T
C
T
t
p
a
(
c
T
c
s
i
F
a
ﬂ
e
m
B
t
C
a
Rapamycin-Generated Murine Th1/Tc1 and Th2/Tc2 Cells 911he rapamycin-induced increase in CD62L might re-
uire T-cell division and thereby operate through a
ell selection mechanism; to evaluate this possibility,
nput CD4 T cells were labeled with CFSE and the
FI of CD62L expression was calculated for Th2 cell
ivisions 0 through 4 (Figure 4B). Consistent with the
ntiproliferative action of rapamycin, we observed that
apamycin-generated Th2 cells divided less than con-
rol Th2 cells did (day 2 of culture; 0 to 2 divisions
ersus up to 4 divisions). In addition, CD4 T cells
hat had not undergone cell division in the rapamycin-
ontaining Th2 cell culture condition had an increase
n CD62L relative to input CD4 cells (increase in MFI
rom 144 to 1285  180). Further, rapamycin in-
reased Th2 cell CD62L expression relative to control
h2 cell cultures for cells that had undergone 1 cell
ivision (CD62L MFI: 1149  49 [Th2.rapa culture]
ersus 218  11 [Th2 culture], P  .0003) or 2 cell
ivisions (CD62L MFI: 674  20 [Th2.rapa culture]
ersus 174  14 [Th2 culture]; P  .0003). As such,
he rapamycin-induced increase in CD62L expression
ccurred on a population and a per-cell basis and
ccurred independent of T-cell division.
apamycin-Generated T Cells: Enhanced
xpansion Upon Repeat Costimulation
In sum, these data indicate that rapamycin pro-
oted the generation of polarized Th1/Tc1 and Th2/
c2 cells of central memory phenotype, as deﬁned by
ncreased CD44 expression, high-level expression of
D62L, and an intermediate level of cytokine and
igure 4. Rapamycin increases CD62L expression independent of
nd baseline expression of CD62L was determined by ﬂow cytomet
uorescence intensity (MFI). A. Four separate cultures of contr
stablished, and the total percentage of Th2 cells expressing CD
ean  SEM of 4 cultures; increased percentage of CD62L ce
. On day 2 of culture, the CFSE-labeled cells in the Th2 and Th2
o have not undergone cell division or to have divided 1, 2, 3, or
D62L expression was determined (results are mean  SEM of 4
t same cell division number, *P  .0001).ytolytic effector function. One functional character-
stic of TCM cells is their increased expansion in re-
ponse to CD28 costimulation relative to TEM cells,
hich are more reliant on alternative costimulatory
athways such as 4-1BBL [26]. To address this biol-
gy, Th1/Tc1 and Th2/Tc2 populations generated
ith or without rapamycin were harvested (day 6 of
ulture), and subjected to repeat CD28 costimulation
n the absence of further rapamycin. Polarization in
he presence of rapamycin yielded T cells with en-
anced capacity for expansion upon repeat CD28 co-
timulation (Figure 5).
apamycin-Generated T Cells: Enhanced
xpansion After Allogeneic BMT
We next evaluated whether such rapamycin-gen-
rated T cells also had an increased capacity to induce
-cell cytokine polarization after allogeneic BMT. As
escribed in Methods, to allow in vivo T-cell tracking,
h1/Tc1 and Th2/Tc2 cells were generated from
D45.1 and CD90.1 congenic donors, respectively.
o evaluate the role of in vitro rapamycin to modulate
he post-BMT balance of Th1/Tc1 and Th2/Tc2
opulations, cohorts received Th1/Tc1 cells (gener-
ted with or without rapamycin) and Th2/Tc2 cells
generated with or without rapamycin) in a 1:1 ratio;
ontrol cohorts that received only Th1/Tc1 or only
h2/Tc2 cells expressed the anticipated type I or II
ytokine proﬁle, respectively, after BMT (data not
hown). Rapamycin-generated Th1/Tc1 cells yielded
ncreased numbers of CD4Th1 and CD8Tc1 cells
division. CD4 T cells were puriﬁed and stained with CFSE dye,
expressed in terms of (A) percentage of positive cells and (B) mean
cells (Th2) or rapamycin-generated Th2 cells (Th2.R) were
s monitored on days 2, 4, 5, and 6 of culture (results shown are
he Th2.R condition relative to the Th2 condition, *P  .0001).
ditions were determined by ﬂow cytometric dye dilution analysis
es; CD4 cells were gated based on cell division, and the MFI of
es; increased CD62L expression in Th2.R cells versus Th2 cellsT-cell
ry and
ol Th2
62L wa
lls in t
.R con
4 tim
cultur
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U. Jung et al.912fter BMT relative to Th1/Tc1 cells not generated in
apamycin (Figure 6A); importantly, post-BMT T cells
n recipients of rapamycin-generated Th1/Tc1 cells had
type I phenotype, with signiﬁcant IFN- secretion
oncomitant with nominal secretion of IL-4 (Figure 6B,
eft panel). Similarly, rapamycin-generated Th2/Tc2
ells yielded increased numbers of CD4Th2 cells and
D8Tc2 cells after BMT relative to Th2/Tc2 cells not
enerated in rapamycin (Figure 6A); most strikingly,
apamycin-generated Th2/Tc2 cells also induced a
arked shift toward type II cytokines after BMT,
ecause T-cell capacity for IL-4 secretion was greatly
ncreased and IFN- secretion was reduced (Figure
B, right panel). In sum, these data indicate that in
itro rapamycin increased the capacity of Th1/Tc1
ells to induce type I polarization after BMT and
ncreased the capacity of Th2/Tc2 cells to induce type
I polarization after BMT.
n Vivo Rapamycin Therapy Downregulates
h1 and Tc1 Effector Cells After BMT
Further in vivo experiments were performed to
valuate the inﬂuence of rapamycin therapy on the
ost-BMT balance of effector Th1/Tc1 and Th2/Tc2
ells. In the data shown in Figure 6, we found that
onor inocula consisting of a 1:1 cell mix of Th1/Tc1
ells generated in rapamycin and Th2/Tc2 cells gen-
rated in the absence of rapamycin induced a Th1/
c1 dominant response after BMT. Therefore, to
tudy the effect of rapamycin on a Th1/Tc1 response,
ohorts received this donor T-cell mix followed by in
ivo therapy with rapamycin or CMC vehicle. Relative
o administration of CMC vehicle, rapamycin therapy
igniﬁcantly reduced the post-BMT absolute number
f CD4Th1 cells and CD8Tc1 cells (Figure 7A).
he rapamycin-mediated reduction in Th1 and Tc1
igure 5. Rapamycin (Rapa)-generated Th1/Tc1 and Th2/Tc2
opulations have increased expansion in response to repeat costimu-
ation. From day 0 to day 6 of culture, Th1/Tc1 or Th2/Tc2 cells
ere generated by costimulation in T1 (A) or T2 (B) polarizing con-
itions without or with rapamycin at concentrations of 0.1 or 10 M.
n day 6 of culture, T cells from each of these 6 conditions were
ashed and restimulated in the absence of further rapamycin; T-cell
xpansion was then monitored from day 6 to day 13 of culture. Each
apamycin generated culture had increased expansion relative to the
elevant control culture not generated in rapamycin (*P .05); resultsaepresent mean values of 3 independent experiments.ell number occurred in part through an antiprolifera-
ive mechanism, because rapamycin therapy signiﬁ-
antly increased the post-BMT frequency of donor
h1/Tc1 cells that maintained expression of CFSE
Figure 7B; 12.5% CFSE Th1/Tc1 cells after CMC
herapy versus 59.7% CFSE Th1/Tc1 cells after
apamycin therapy, P  .05). Rapamycin therapy
early completely abrogated post-BMT T-cell capac-
ty for IFN- secretion; capacity for IL-2 secretion
as also reduced, but this difference did not reach
tatistical signiﬁcance. In the setting of this downregu-
ation of Th1-type cytokines, there was no associated
ncrease in secretion of the type II cytokines IL-4,
L-5, IL-10, or IL-13 (Figure 7C). As such, after
doptive transfer of rapamycin-generated Th1/Tc1
ells that expressed a TCM differentiation proﬁle, in
ivo rapamycin inhibited Th1 and Tc1 cell number
fter BMT and inhibited post-BMT type I cytokine
ecretion, but did not induce a type I to a type II shift
n cytokine proﬁle.
ffector Th2 and Tc2 Cells Are Relatively
esistant to In Vivo Rapamycin Therapy
Cohorts were also included to assess whether
apamycin therapy modulated Th2/Tc2-driven in
ivo responses. For this assessment, cohorts received a
:1 donor cell mix that consisted of Th2/Tc2 cells
enerated in the presence of rapamycin and Th1/Tc1
ells generated in the absence of rapamycin, because
his T-cell combination yielded a highly polarized
ype II cytokine secretion proﬁle after BMT (Figure
B). Relative to administration of drug vehicle, rapa-
ycin modestly reduced the post-BMT absolute
umber of CD4Th2 cells, and actually increased the
umber of CD8Tc2 cells after BMT (Figure 8A).
urther, rapamycin therapy yielded a relatively mod-
st antiproliferative effect on the Th2/Tc2 population
Figure 8B; 9.9% CFSE Th2/Tc2 cells after CMC
herapy versus 34.0% CFSE Th2/Tc2 cells after
apamycin therapy, P  .05). Rapamycin therapy did
ot signiﬁcantly reduce type II cytokine polarization,
ecause rapamycin resulted in a statistically signiﬁcant
eduction in post-BMT capacity for IFN- secretion
nd did not abrogate IL-4 secretion capacity. How-
ver, rapamycin resulted in a statistically signiﬁcant
eduction in IL-13 secretion capacity; the capacity for
ecretion of the type II cytokines IL-5 and IL-10 was
lso reduced, but this difference did not reach statis-
ical signiﬁcance (Figure 8C). Of note, in this exper-
ment, which involved administration of TEM-like
h1/Tc1 cells generated without rapamycin, in vivo
apamycin therapy did not reduce Th1 or Tc1 cell
umber and only modestly reduced post-BMT IFN-
ecretion. In sum, these data indicate that Th2/Tc2
esponses generated from TCM-like effectors were rel-
tively resistant to in vivo rapamycin therapy.
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Rapamycin-Generated Murine Th1/Tc1 and Th2/Tc2 Cells 913apamycin-Generated Th1/Tc1 Cells Mediate
ncreased Lethal GVHD: Attenuation by
n Vivo Rapamycin Therapy
Given the immunosuppressive nature of rapamy-
in and its known capacity to promote type II cytokine
olarity in vivo, our observations that rapamycin-gen-
rated Th1/Tc1 cells had increased expansion and
aintained a type I cytokine phenotype in vivo were
ot initially predicted. Given this new information, we
ypothesized that rapamycin-generated Th1/Tc1
ells would generate increased GVHD relative to con-
rol Th1/Tc1 cells. Consistent with this hypothesis,
e found that the median survival after fully major
istocompatibility complex disparate BMT in recipi-
nts of rapamycin-generated Th1/Tc1 cells was only 7
ays (Figure 9A); by comparison, median post-BMT
urvival in recipients of control Th1/Tc1 cells had not
et been met at 40 days after BMT (P  .027).
igure 6. Rapamycin-generated Th1/Tc1 and Th2/Tc2 cells have i
ells were generated with (10 M; T1.R and T2.R) or without (
xperiments, T1 or T1.R cells were generated from CD45.1 dono
xpanded parental T cells were injected intravenously into lethally
2 cells, T1.R and T2 cells, or T1 and T2.R cells (each population
D4Th1, CD4Th2, CD8Tc1, and CD8Tc2 cells was calcu
ytokine phenotype, spleen cells were adjusted to 0.5  106 cells/m
nd IL-4 content by ELISA. Each result is the mean  SEM of 5
ith cohort receiving T1 and T2 cells generated without rapamyciBecause rapamycin-generated Th1/Tc1 cells were mensitive to inhibition by a short 5-day course of in
ivo rapamycin therapy (Figure 7), we further hypoth-
sized that the lethal GVHD mediated by this T-cell
opulation might be attenuated by short-course rapa-
ycin therapy after BMT. We found that rapamycin
herapy attenuated lethal GVHD mediated by rapa-
ycin-generated Th1/Tc1 cells, because median
ost-BMT survival increased from 7 to 31 days after
MT (Figure 9B; P  .022). In contrast, GVHD
ediated by control Th1/Tc1 cells was unexpectedly
ncreased by rapamycin therapy, because median post-
MT survival was reduced from 40 to 7 days after
MT with rapamycin therapy (P  .024).
ISCUSSION
Although the immunosuppressive effect of rapa-
d expansion in vivo after allogeneic BMT. Th1/Tc1 and Th2/Tc2
T2) rapamycin. To allow cell tracking in vivo after cell mixing
reas T2 or T2.R cells were generated from CD90.1 donors. The
ted CB6F1 hosts; cohorts shown received a 1:1 cell mix of T1 and
06 cells injected). A. On day 5 after BMT, the absolute number of
y total spleen cell counts and ﬂow cytometry. B. For post-BMT
costimulated for 24 hours; the supernatants were tested for IFN-
s per cohort; *P  .05, statistically signiﬁcant difference comparedncrease
T1 and
rs, whe
irradia
, 5  1
lated b
L and
subjectycin has been recognized for decades, characteriza-
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U. Jung et al.914ion of the molecular and cellular mechanisms of rapa-
ycin action is broadening and clinical application
f rapamycin is expanding. In this study, we evaluated
ne putative cellular mechanism of rapamycin action
modulation of Th1/Th2 and Tc1/Tc2 cell subset
ifferentiation) and one potential application of rapa-
ycin (ex vivo and in vivo usage of rapamycin for
odulation of the post-BMT balance of polarized
-cell subsets).
Contrary to our hypothesis, we found that rapamy-
in did not differentially inﬂuence donor T-cell polar-
zation toward polarized Th1/Tc1 and Th2/Tc2 cell
ubsets. That is, across a broad range of rapamycin con-
entrations, costimulation in the presence of IL-12 and
eutralizing antibody to IL-4 yielded T cells with a
h1/Tc1 phenotype, as deﬁned by the secretion of type
cytokines and the mediation of fas-based cytolysis. Our
bservation that in vitro rapamycin did not inhibit Th1/
c1 cell differentiation or cause a Th1/Tc1 to Th2/Tc2
hift stands in contrast to previous in vivo results, where
igure 7. Rapamycin (Rapa) therapy inhibits Th1/Tc1 cells in vi
esponse, donor T-cell inocula consisted of rapamycin-generated Th
dministered at a 1:1 ratio (5  106 of each population) into lethally
MC vehicle or rapamycin (1.5 mg · kg1 · d1  5 days). On day
y total spleen cell counts and ﬂow cytometry (A), and the perce
ost-BMT cytokine phenotype, splenic single cells were harvested
ollected and cytokine content was evaluated by ELISA. Results are
ifference between CMC and Rapa cohorts (*P  .05). Similar resapamycin has been shown to promote a shift toward nells of Th2 and Tc2 phenotypes [12,13]. Our ﬁndings
ndicate that the in vitro T-cell expansion method that
e used, which includes APC-independent costimula-
ion and exogenous IL-12, provides essential signals re-
uired for Th1/Tc1 cell differentiation that function
ndependent of rapamycin. Such signals may not be
rovided in other models where APCs are operational,
ecause rapamycin has been shown to inhibit APCs
hrough mechanisms that include downregulation of co-
timulatory molecule expression [9] and IL-12/IL-18
ytokine pathways [27]. Because rapamycin does not
ppear to differentially modulate T-cell polarization
athways in a direct manner, the full diversity of Th1,
c1, Th2, and Tc2 populations can be generated in
apamycin, thereby offering an opportunity to explore
he potential utility of these populations via adoptive
-cell therapy. Of note, a recent study reported the
eneration of CD4 T regulatory cells in rapamycin
sing an APC-free method [28], thereby providing an-
ther example of the diversity of T-cell phenotypes ame-
r BMT. To study the effect of rapamycin on a Th1/Tc1-driven
cells and Th2/Tc2 cells generated without rapamycin. T cells were
ted CB6F1 hosts; after BMT, recipients of this T-cell mix received
BMT, the number of Th1, Th2, Tc1, and Tc2 cells was calculated
of Th1/Tc1 cells retaining CFSE dye was measured (B). C. For
5 after BMT and costimulated; after 24 hours, supernatants were
 SEM of 5 subjects per cohort; there was a statistically signiﬁcant
re observed in a second experiment.vo afte
1/Tc1
irradia
5 after
ntage
at day
meanable to expansion in rapamycin.
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Rapamycin-Generated Murine Th1/Tc1 and Th2/Tc2 Cells 915Three aspects of our data suggest that rapamy-
in facilitates the generation of CD4Th1/Th2 and
D8Tc1/Tc2 cells with a central-memory effec-
or phenotype. First, rapamycin greatly increased
-cell expression of CD62L, which is a marker for
CM cells [29]. Of note, the rapamycin-induced
ncrease in CD62L was observed at a population
evel and a per-cell basis and did not require T-cell
ivision; as such, “selection” for CD62L-expressing
cells during rapamycin exposure does not likely
epresent the primary mechanism for the observed
D62L increase. It is possible that reduced CD62L
hedding and upregulation of mRNA transcription
epresent alternative mechanisms; regarding this
atter possibility, we recently found that rapamycin-
enerated Th2 cells have greatly increased CD62L
RNA (data not shown). Our in vitro ﬁndings are
onsistent with the in vivo results of Blazar et al [13]
ho demonstrated that rapamycin prevention of
urine GVHD was associated with increased donor
igure 8. Effector Th2/Tc2 cells are relatively resistant to rapam
h2/Tc2-driven response, donor T-cell inocula consisted of rap
apamycin. T cells were administered at a 1:1 ratio (5  106 of eac
f this T-cell mix received CMC vehicle or rapamycin (1.5 mg · kg
nd Tc2 cells was calculated by total spleen cell counts and ﬂow cyt
easured (B). C. For post-BMT cytokine phenotype, splenic single
upernatants were collected and cytokine content was evaluated by E
he CMC and Rapa cohorts was statistically signiﬁcant (*P  .05).-cell expression of CD62L. Also consistent withther studies, we found that, in the absence of
apamycin, Th1 cells expressed increased CD62L
elative to Th2 cells [30,31]. Although we found
hat rapamycin upregulated CD62L on each T-cell
ubset evaluated, this effect was particularly prom-
nent for the Th2 and Tc2 subsets, because these
opulations expressed nominal CD62L in the ab-
ence of rapamycin. Second, rapamycin-generated
cells expressed an intermediate level of T-cell
ffector function that is characteristic of TCM cells,
ncluding reduced magnitude of cytokine secretion,
educed secretion of “distal” type II cytokines such
s IL-5, IL-10, and IL-13, and reduced cytolytic
unction [29]. Third, similar to other studies of
doptive T-cell transfer that have observed in-
reased in vivo effects of CD62L-expressing TCM
ype cells [15-19], we found that each of the rapa-
ycin-generated T-cell subsets had increased ex-
ansion after BMT and yielded a more marked
olarization in the post-BMT cytokine proﬁle.
apa) therapy after BMT. To study the effect of rapamycin on a
-generated Th2/Tc2 cells and Th1/Tc1 cells generated without
lation) into lethally irradiated CB6F1 hosts; after BMT, recipients
1  5 days). On day 5 after BMT, the number of Th1, Th2, Tc1,
(A), and the percentage of Th2/Tc2 cells retaining CFSE dye was
ere harvested at day 5 after BMT and costimulated; after 24 hours,
Results are means  SEM of 5 per cohort; the difference between
results were observed in a second experiment.ycin (R
amycin
h popu
1 · d
ometry
cells w
LISA.In recent experiments, we demonstrated that the
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U. Jung et al.916ncreased capacity of rapamycin-generated T cells to
odulate the post-BMT cytokine phenotype has im-
ortant implications for allograft manipulation strat-
gies, because Th2 cells generated in rapamycin were
ore effective than control Th2 cells for GVHD
revention [14]. The present data predict that use of
n vitro rapamycin to generate Tc2, Th1, or Tc1 cells
ay enhance additional adoptive T-cell therapy appli-
ations. As an example, we recently showed that co-
timulated donor Tc2 cells abrogate murine graft re-
ection [32]; in light of the data demonstrating that
c2 cells generated in rapamycin are present in in-
reased numbers after BMT and contribute to en-
anced type II polarization, we are currently testing
he hypothesis that rapamycin-generated donor Tc2
A
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igure 9. Rapamycin-generated Th1/Tc1 cells mediate increased
6-into-BALB/c BMT was performed using 850 cGy of host irrad
 10) or in combination with a separate infusion of ex vivo gener
apamycin-exposed Th1/Tc1 cells (Th1/Tc1.R; 1  107 cells/recipi
ellulose drug vehicle (intraperitoneally) for the ﬁrst 5 days after BM
urvival in Th1/Tc1.R cohort versus Th1/Tc1 cohort). B. Addition
ost-BMT rapamycin therapy (Th1/Tc1.R  Rapamycin Tx; left pa
nd post-BMT rapamycin therapy (Th1/Tc1  Rapamycin Tx; righ
h1/Tc1.R recipients; **P  .024, rapamycin therapy increased letells might be particularly enriched in their capacity to rbrogate graft rejection. In addition, we found that
llogeneic Th1/Tc1 cells generated in rapamycin me-
iated increased in vivo effects, because recipients of
h1/Tc1.rapa cells had increased lethal GVHD rela-
ive to recipients of control Th1/Tc1 cells. Further
tudies will be required to evaluate whether the en-
anced in vivo function of rapamycin-generated Th1/
c1 cells might be harnessed for therapeutic purposes
uch as mediation of syngeneic GVT effects.
Our ﬁndings also extend prior observations that
upport the existence of “rapamycin-resistant” T-cell
opulations, which have previously been identiﬁed
ithin human CD8 T cells that are promoted
hrough increased strength of CD28 costimulation
33]. Although we found that rapamycin-resistant mu-
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GVHD: attenuation by in vivo short-course rapamycin therapy.
ollowed by marrow infusion alone (BMT; 1  107 cells/recipient;
ntrol Th1/Tc1 cells (Th1/Tc1; 1  107 cells/recipient, n  10) or
 20); each of these cohorts was administered the carboxy-methyl-
Survival results for these 3 cohorts are shown (*P  .027, reduced
rts in this experiment received the Th1/Tc1.R cells and 5 days of
amycin dose of 1.5 mg · kg1 · d1; n  20) or the Th1/Tc1 cells
l; n  10). *P  .022, rapamycin therapy reduced lethal GVHD in
HD in Th1/Tc1 recipients. 
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Rapamycin-Generated Murine Th1/Tc1 and Th2/Tc2 Cells 917x vivo in an APC-free system, we documented dif-
erential in vivo resistance to rapamycin, with effector
h1/Tc1 cells having increased sensitivity to rapamy-
in therapy relative to effector Th2/Tc2 cells. This
nding suggests that the previously observed shift
oward Th2/Tc2 responses with rapamycin therapy
13] is the result of a Th2/Tc2 “default” pathway, and
ot due to interconversion of Th1/Tc1 cells to a
h2/Tc2 phenotype. We speculate that this differen-
ial in vivo sensitivity to rapamycin may relate to an
ndirect pathway whereby rapamycin inhibits APC
unction, with subsequent preferential downregula-
ion of Th1/Tc1 cell responses; current experiments
n the laboratory seek to characterize the APC func-
ional deﬁcits induced by rapamycin after BMT. From
n application standpoint, our results suggest that, for
llograft modulation approaches aimed towards Th2/
c2 skewing, the combination of in vitro rapamycin
or T-cell generation and post-BMT rapamycin ther-
py may preferentially limit Th1/Tc1 responses while
reserving Th2/Tc2 responses. However, because rapa-
ycin reduced Th1 and Tc1 cell number, inhibited
ost-BMT type I cytokine secretion, and attenuated le-
hal GVHD mediated by TCM-like Th1/Tc1.R cells but
ot TEM-like control Th1/Tc1 cells, in vivo rapamycin
ay inhibit only relatively early-stage effector T cells.
In conclusion, rapamycin represents a unique im-
une modulation agent that does not differentially
odulate T-cell cytokine phenotype in a direct man-
er. Rather, rapamycin is permissive for substantial
h1/Tc1 and Th2/Tc2 polarization, at least under
onditions where polarization occurs in an APC-inde-
endent manner. Use of in vitro rapamycin during
-cell polarization may have signiﬁcant application as
n adoptive T-cell therapeutic approach, because the
CM cells generated through this method mediate
nhanced in vivo effects. In vivo rapamycin therapy
reates a supportive post-BMT milieu for Th2/Tc2
ell therapies, because such populations are relatively
pared, whereas Th1/Tc1 cell responses are preferen-
ially inhibited.
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